𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate

✍ Scribed by Timothy A. Olson; D. Mohanraj; Sabita Roy; S. Ramakrishnan

Publisher
John Wiley and Sons
Year
1997
Tongue
French
Weight
368 KB
Volume
73
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Tumor-derived vascular endothelial growth factor (VEGF)/ vascular permeability factor (VPF) plays an important role in neovascularization and the development of tumor stroma. Furthermore, VEGF receptors are over-expressed in the endothelial cells of tumor vasculature and almost non-detectable in the vascular endothelium of adjoining normal tissues. The differential expression of receptor offers a selective advantage for targeting cytotoxic toxin polypeptides. We have prepared a vascular targeting reagent by chemically linking recombinant VEGF to a truncated form of diphtheria toxin. The VEGF-toxin conjugate was selectively toxic to endothelial cell lines and inhibited experimental neovascularization of the chick chorioallantoic membrane. In the present study, we examined the effects of VEGF-toxin conjugate on solid tumor growth. Athymic nude mice with established subcutaneous tumors were treated with daily intraperitoneal injections of the VEGF-toxin conjugate or free toxin. When compared with control animals treated with the toxin polypeptide alone, the conjugate-treated animals displayed a significant inhibition of tumor growth. Histological analysis of tumors from conjugate-treated animals revealed hemorrhagic necrosis consistent with a vascular-mediated injury. In contrast, highly vascularized normal tissues from conjugate-treated animals demonstrated no evidence of hemorrhage or tissue injury. The conjugate was well tolerated without apparent toxicities. Our results illustrate the anti-tumor activity of a VEGF-toxin conjugate selectively targeting the tumor neovasculature.

📜 SIMILAR VOLUMES

Tumor-targeting properties of antibody–v
Tumor-targeting properties of antibody–vascular endothelial growth factor fusion proteins
✍ Cornelia Halin; Uwe Niesner; Maria Elena Villani; Luciano Zardi; Dario Neri 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 293 KB

## Abstract A major problem of antibody‐based targeting of solid tumors is the poor penetration of antibodies into tumor tissue. Vasoactive immunoconjugates have been proposed as a means of increasing antibody uptake in tumors. In principle, VEGF (also known as vascular permeability factor) could s

Modulation of angiogenic vascular endoth
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis
✍ Ewa M. Paleolog; Sylvia Young; Alison C. Stark; Richard V. McCloskey; Marc Feldm 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 804 KB

## Objective: To investigate the regulation of expression of the angiogenic cytokine vascular endothelial growth factor (vegf) in rheumatoid arthritis (ra), in order to determine whether new blood vessel formation could be a potential therapeutic target in ra. ## Methods: Dissociated ra synovial

Stromal cell-derived factor-1 stimulates
Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor
✍ Krishna Reddy; Zhichao Zhou; Shu-Fang Jia; Tim H. Lee; Jaime Morales-Arias; Ying 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 292 KB 👁 1 views

## Abstract Stromal cell‐derived Factor‐1α (SDF‐1α) stimulates the migration of bone marrow (BM) cells, similar to vascular endothelial growth factor (VEGF). We previously demonstrated that inhibition of VEGF~165~ by small interfering RNA inhibited Ewing's sarcoma tumor growth, tumor vessel formati

Concentration of vascular endothelial gr
Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors
✍ Holzer, Gerold ;Obermair, Andreas ;Koschat, Martin ;Preyer, Oliver ;Kotz, Rainer 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

## Abstract ## Background Vascular endothelial growth factor (VEGF) is recognized as an important stimulator of angiogenesis. Formation of new blood vessels by angiogenic factors occurs in many biological processes, both physiological and pathological, among others in growth of primary solid malig

Immunodetection and quantification of va
Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues
✍ Hiroko Bando; Maren Brokelmann; Masakazu Toi; Kari Alitalo; Jonathan P. Sleeman; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 303 KB

## Abstract Vascular endothelial growth factor recpetor‐3 (VEGFR‐3) and its ligands, vascular endothelial growth factor‐C (VEGF‐C) and –D (VEGF‐D), are the major molecules involved in developmental and pathological lymphangiogenesis. Here we describe for the first time the development of a specific